These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7966131)

  • 1. Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors: heterocyclic ring systems containing P1' and P2' substituents.
    Kitchin J; Bethell RC; Cammack N; Dolan S; Evans DN; Holman S; Holmes DS; McMeekin P; Mo CL; Nieland N
    J Med Chem; 1994 Oct; 37(22):3707-16. PubMed ID: 7966131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors containing a stereochemically unique peptide isostere.
    Holmes DS; Bethell RC; Cammack N; Clemens IR; Kitchin J; McMeekin P; Mo CL; Orr DC; Patel B; Paternoster IL
    J Med Chem; 1993 Oct; 36(21):3129-36. PubMed ID: 8230099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A series of penicillin-derived C2-symmetric inhibitors of HIV-1 proteinase: structural and modeling studies.
    Wonacott A; Cooke R; Hayes FR; Hann MM; Jhoti H; McMeekin P; Mistry A; Murray-Rust P; Singh OM; Weir MP
    J Med Chem; 1993 Oct; 36(21):3113-9. PubMed ID: 8230097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships.
    Humber DC; Bamford MJ; Bethell RC; Cammack N; Cobley K; Evans DN; Gray NM; Hann MM; Orr DC; Saunders J
    J Med Chem; 1993 Oct; 36(21):3120-8. PubMed ID: 8230098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
    Thompson SK; Murthy KH; Zhao B; Winborne E; Green DW; Fisher SM; DesJarlais RL; Tomaszek TA; Meek TD; Gleason JG
    J Med Chem; 1994 Sep; 37(19):3100-7. PubMed ID: 7932533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
    De Lucca GV; Liang J; De Lucca I
    J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and analysis of a series of C2-symmetric HIV-1 proteinase inhibitors derived from penicillin.
    Gray NM; Cameron JM; Cammack N; Cobley KN; Holmes DS; Humber DC; Orr DC; Penn CR; Potter R; Madar S
    Anal Biochem; 1994 Jan; 216(1):89-96. PubMed ID: 8135370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
    Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg NE; Kempf D; Norbeck DW; Plattner JJ
    Biochem Biophys Res Commun; 1996 Aug; 225(2):436-40. PubMed ID: 8753780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.
    Mühlman A; Classon B; Hallberg A; Samuelsson B
    J Med Chem; 2001 Oct; 44(21):3402-6. PubMed ID: 11585445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.
    Ghosh AK; Lee HY; Thompson WJ; Culberson C; Holloway MK; McKee SP; Munson PM; Duong TT; Smith AM; Darke PL
    J Med Chem; 1994 Apr; 37(8):1177-88. PubMed ID: 8164260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A symmetric inhibitor binds HIV-1 protease asymmetrically.
    Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
    Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penicillin derived C2-symmetric dimers as novel inhibitors of HIV-1 proteinase.
    Humber DC; Cammack N; Coates JA; Cobley KN; Orr DC; Storer R; Weingarten GG; Weir MP
    J Med Chem; 1992 Aug; 35(16):3080-1. PubMed ID: 1501235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.